title: Positive and negative aspects of the human immunodeficiency virus protease: development of inhibitors versus its role in AIDS pathogenesis.
abstract: In this review we summarize multiple aspects of the human immunodeficiency virus (HIV) protease from both structural and functional viewpoints. After an introductory overview, we provide an up-to-date status report on protease inhibitors (PI). This proceeds from a discussion of PI structural design, to how PI are optimally utilized in highly active antiretroviral triple therapy (one PI along with two reverse transcriptase inhibitors), the emergence of PI resistance, and the natural role of secretory leukocyte PI. Then we switch to another focus: the interaction of HIV protease with other genes in acute and persistent infection, which in turn may have an effect on AIDS pathogenesis. We conclude with a discussion on future directions in HIV treatment, involving multiple-target anti-HIV therapy, vaccine development, and novel reactivation-inhibitory reagents.
authors: Department of Virology, Research Institute for Microbial Diseases (Biken), Osaka University, Suita, Osaka 565-0871, Japan. ikuta@biken.osaka-u.ac.jp
authors: K
authors: K
authors: Ikuta
authors: S
authors: S
authors: Suzuki
authors: H
authors: H
authors: Horikoshi
authors: T
authors: T
authors: Mukai
authors: R B
authors: RB
authors: Luftig
mesh_terms: D016915:AIDS Vaccines; D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000209:etiology*; D002986:Clinical Trials as Topic; D015195:Drug Design; D004358:Drug Therapy / Q000639:trends; D005814:Genes, Viral; D016333:HIV Protease / Q000187:drug effects*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D015497:HIV-1 / Q000472:pathogenicity; D006801:Humans; D017735:Virus Latency
chemical_list: D016915:AIDS Vaccines; D017320:HIV Protease Inhibitors; D016333:HIV Protease